Malignant lymphomas represent a heterogeneous group of B and T cell-derived tumors. Most entities respond to chemo-and/or radiotherapy and, depending on the histological subtype, up to 80% complete remissions (CR) can be achieved. The main reason for tumor recurrence is the development of lymphoma cell clones resistant to the initial therapy. The use of monoclonal antibodies (MoAbs) or other immunotherapeutic strategies may be useful to eradicate such chemotherapy-resistant tumor cells. Clinical trials in lymphoma patients showed a strong correlation between poor outcome and the presence of minimal residual disease, which can be detected by polymerase chain reaction (PCR) 1 at very high sensitivity. Also, autologous stem cell preparations from patients with lymphomas frequently contain residual lymphoma cells. Since residual lymphoma cells may contribute to an overt clinical relapse, the elimination of these residual cells may have a great clinical impact and is followed in purging strategies.
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Results and discussion

Native monoclonal antibodies
Since the first description of therapy using monoclonal antibodies in 1979, several phase I and II trials have been initiated to evaluate both safety and antitumoral activity of this approach. Native MoAbs can kill a tumor cell through various mechanisms including complement activation, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis of antibody-coated tumor cells, inhibition of cell cycle progression, and induction of apoptosis.
2,3 Alternatively, MoAbs can eliminate a tumor cell by inhibiting growth factor receptors or molecules involved in signal transduction and cell proliferation.
The group of R Levy at Stanford reported on promising results in B-lymphocytic malignancies using anti-idiotypic monoclonal antibodies (anti-Id MoAbs). 4, 5 Side-effects were moderate and included chills, fever, dyspnea, nausea, diarrhea, myalgia, and the development of human antimouse antibodies (HAMA). Complete and partial remissions had been observed together with a strong correlation of anti-Id MoAb-mediated signal transduction and tumor regression as measured by the induction of cellular protein tyrosine phosphorylation. 6 Several trials evaluated the effect of the Campath-1H MoAb directed against the CDw52 antigen, expressed on B and T cell lymphomas. In addition to common side-effects such as fever, rigor and neutrocytopenia, severe opportunistic infections due to the depletion of CD4-and CD8-positive T lymphocytes were reported. 7 High response rates up to 70% were reported when Campath-1H was administered in CLL patients. 8 Exciting results have been demonstrated in clinical phase I/II trials with the chimeric mouse/human anti-CD20 MoAb IDEC-C2B8 (IgG1), which binds complement and induces ADCC as well as programmed cell death (apoptosis).
2 A large phase II trial revealed a response rate of 50% in low and intermediate grade lymphomas with significantly better responses in patients with low tumor masses. At our department more than 80 patients with relapsed or refractory lymphomas including mantle cell lymphomas were treated with IDEC-C2B8 so far and toxicities were generally low. However, patients with a higher tumor load in the peripheral blood developed signs of severe cytokine release. 9 Current trials investigate the role of anti-CD20 antibody treatment in high grade lymphomas and in combination with chemotherapy.
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Radioimmunoconjugates
Radioimmunoconjugates may offer a number of advantages: (1) endocytosis is not required for cytotoxicity; (2) the use of an isotope enables the eradication of antigennegative 'bystander' tumor cells; (3) radioimmunoconjugates allow biodistribution experiments to detect the localization of the conjugate at the tumor site. Antibodies can either be labeled directly using 131 In) using bifunctional chelating agents.
Several clinical trials using non-myeloablative and myeloablative doses of radiolabeled MoAbs (R-MoAbs) were conducted in lymphoma patients. Excellent response rates were achieved with the 131 I-labeled B1 MoAb against the CD20 antigen using a single non-myeloablative dose of 30-160 mCi in patients with refractory lymphomas. 10 Of 28 treated patients, 14 achieved a CR and eight PR. Nonhematologic toxicities were generally mild but hematologic toxicities proved dose-limiting.
High-dose radioimmunotherapy seems to be even more superior compared to low-dose therapy. Out of 43 patients with relapsed NHL, which were initially trace-labeled, 24 demonstrated satisfactory tumor imaging. 11 Subsequently, these patients received a single infusion of the R-MoAb up to 777 mCi. The dose limiting myelosuppression required reinfusion of autologous bone marrow in 15/19 patients. Two PR and 16 CR were observed among 24 patients, and nine patients remained in CR over a period of 3 to 53 months. In a recently published phase II trial, 21 patients were treated with therapeutic doses (345-785 mCi) of 131 I-B1, 12 with subsequent autologous stem cell transplantation. A summary of these phase I/II studies showed an overall survival of 93% with a median follow-up of 2 years.
In contrast to ␥-emitters, ␤-emitters deliver sufficient doses over a distance of 100 to 1000 cell diameters without the need for hospitalization. In a recently published trial, 13 90 Y-labeled anti-Id MoAbs were used for the treatment of nine patients with refractory NHL. Toxicities were mild and two patients achieved a CR and one patient a PR.
Immunotoxins
Immunotoxins (ITs) can selectively bind and destroy their specific target cell upon internalization.
14 They consist of a binding chain (usually a monoclonal antibody) and a toxin molecule, either covalently bound via a chemical crosslinker or generated genetically by recombinant technology. The toxin is of plant or bacterial origin and includes in most instances ribosome-inactivating proteins to arrest protein synthesis. 15 Ricin is a plant toxin most frequently used for the construction of chemically linked ITs. ITs were also generated using recombinant DNA technology by the fusion of antibody V H genes to bacterial toxins such as diphtheria toxin (DT) 16 or Pseudomonas exotoxin-A (ETA). 17 Vitetta and colleagues 38 used anti-CD22 and anti-CD19 antibodies coupled to deglycosylated ricin A-chain (dgA) for the treatment of B-NHL with dose-limiting toxicities (DLT) including vascular leak syndrome, fever and myalgia. In 5/14 patients a PR of short duration was observed.
Bone Marrow Transplantation
Grossbard and colleagues 39 performed similar phase I studies in patients with B-NHL using the anti-CD19 MoAb B4 coupled to blocked ricin (bR). In this study nine out of 25 patients developed HAMA and HARA, and one CR and two PR were reported. In a phase II trial, 50 patients were treated with ITs after high-dose chemotherapy and stem cell transplantation at a reduced dose of 30 g/kg/day over 7 days. In 34 evaluable patients no relapse occurred between 1 and 3 years after transplantation. The Cancer and Acute Leukemia Group B (CALGB) initiated a randomized multicenter phase III study in which patients in CR after highdose chemotherapy receive anti-B4-bR over a 7-day period). 18 
Bispecific monoclonal antibodies
Bispecific monoclonal antibodies (BiMAbs) recognize two different antigens via their two binding sites. 19 BiMAbs can be used to crosslink lymphoma cells with immunological effector cells like macrophages, T cells or NK cells which can lyse tumor cells. An alternative approach is the design of BiMAbs directed against a tumor cell antigen and a prodrug-converting enzyme such as alkaline phosphatase to convert relatively non-toxic cytostatic prodrugs like mitomycin phosphate or etoposide phosphate into the active cytostatic drugs mitomycin and etoposide, respectively. In addition, toxins like saporin or radioisotopes conjugated to haptens can be targeted to tumor cells via BiMAbs.
BiMAbs can be generated by chemical crosslinking of two monoclonal antibodies or F(abЈ) fragments, 20 by somatic fusion of two distinct hybridoma cell lines (hybridhybridomas or tetradoma), 19 or by recombinant antibody technology. 21 Most BiMAbs aim to activate T cells by crosslinking of the TCR/CD3 complex. 22 After binding of the BiMAb to the TCR/CD3 complex, the T-lymphocytes become pre-activated requiring further stimulation to fully exert their cytotoxic activity. 23 The additional costimulating molecule can be provided by cytokines such as IL-2, IL-12, and TNF-␣, or by CD28-mediated costimulation.
Haagen et al 24 tested several CD3xCD19 BiMAbs against B cell lines and primary lymphoma cells. These BiMAbs induced remarkable cytotoxic activity in the presence of activated T cells, as well as proliferation and cytotoxicity in resting T cells. We used bispecific CD3xCD19 antibodies together with monospecific antibodies recognizing the CD28-molecule on T lymphocytes. Our results show that CD3xCD19 bispecific antibodies in combination with CD28 monospecific antibodies can activate T cells to lyse autologous lymphoma cells in vitro and in vivo. In a clinical trial with 10 patients with relapsed B cell lymphoma who were treated with a locoregional application of CD3xCD19 bispecific antibodies together with CD28 antibodies only moderate toxicities were found. The analysis of immunological responses revealed temporary increases in the T/B-ratio of the peripheral blood, as well as enhanced natural killer cell activity.
A phase I trial with three patients with low-and intermediate-grade NHL receiving CD3xCD19 BiMAb (SHR-1) i.v. over 0.5 h in escalating doses ranging from 10 g on day 1 to 5 mg on day 9, 25 showed moderate toxicities inclusing chills, fever, and thrombocytopenia. Transient decreases in splenomegaly and lymphoma occured in two of three patients. There were no detectable human antimouse or anti-rat antibodies. Another clinical investigation in four patients suffering from end-stage low-grade B-NHL used a cocktail of two different BiMAbs directed against different epitopes on the CD22 antigen and saporin. 26 All patients showed rapid but transient reduction of tumor volume.
BiMAb-mediated phagocytosis of malignant cells can be achieved through targeting of macrophages.
27 F(abЈ) fragments recognizing the B cell differentiation markers CD19 and CD37 were chemically linked to the F(abЈ) portion of a MoAb which reacts with Fc␥RI/CD64 expressed on monocytes, macrophages and dendritic cells. Both BiMAbs mediated tumor cell lysis by monocyte-derived macrophages.
Vaccination with monoclonal antibodies
Vaccination against tumor-associated antigens is limited by the problem of obtaining sufficient amounts of purified antigen, as well as the poor immune response due to tolerance against autologous tumor antigens. 28 However, active specific immunotherapy circumventing tumor tolerance is implied by the network theory. 29 This hypothesis suggests that tumor antigen-like structures within the antigenic environment of anti-idiotypic determinants are presented on variable regions of immunoglobulins. According to the network theory by Jerne, 29 idiotopes can induce a cascade of idiotypic antibodies termed Ab1, Ab2, Ab3, etc. The Ab2 is an anti-idiotypic antibody directed against the variable region of the anti-tumor antibody (Ab1), thereby mimicking the conformation of the original antigen like an internal image. Thus, Ab2 itself can induce specific anti-tumor response in the absence of the original tumor antigen and can therefore serve as a vaccine.
Immune responses can also be elicited against the surface-Ig idiotypes expressed on malignant B cells. 30 Active immunization against idiotypic determinants on murine B cell lymphoma was demonstrated to inhibit tumor growth. 31 An improved immune response requires conjugation of the Ig to a immunogenic carrier protein like keyhole-limpet hemocyanin (KLH). 32 In a clinical trial conducted by Levy et al, 9 NHL patients in clinical remission after chemotherapy were immunized with idiotype derived from their B cell lymphoma. Lymphoma cells obtained from tumor biopsies of these patients were fused with a heterohybridoma. The Ig-idiotype was isolated from the cell culture supernatant, conjugated to KLH, and subsequently used as vaccine. Two patients showed humoral responses to the Igidiotype, four patients had a cellular response, and one patient both. Side-effects were mild and two patients with measurable disease had CR up to 24 months, six patients remained disease-free up to 10 months and one patient had an early relapse.
A recent vaccination approach employs dendritic cells, which have been demonstrated to be the most effective antigen-presenting cells. 33 These cells express high levels of adhesion molecules like ICAM-1 and LFA-3, as well as MHC-I, MHC-II and immunostimulatory proteins such as CD80 (B7-1), CD86 (B7-2), and CD40. 31 Hsu et al 34 immunized four NHL patients with autologous ex vivo generated dendritic cells pulsed with idiotypic protein. None of the patients developed anti-idiotypic antibodies, however, in all patients a substantial increase in the lymphoma-specific cellular response was demonstrated. The complete remission observed in one patient was most likely due to a specific cytotoxic T cell effect. Another patient with minimal residual disease that was only detectable by PCR converted to be PCR-negative. We currently investigate this approach in patients with multiple myeloma. In our study myeloma patients are vaccinated with autologous dendritic cells pulsed with the patient's paraprotein. Twelve patients were vaccinated by this approach. Four patients developed idiotype-specific antibodies and in three patients an idiotype-specific T cell response could be detected.
Conclusions
The major goal in future studies is the treatment of residual disease in patients who have undergone first-or secondline treatment. The combination of different therapeutic strategies, ie chemotherapy, radiotherapy, and immunotherapy, will probably increase therapeutic efficacy and thereby the clinical outcome of the patients. Despite the promising results using unconjugated MoAbs, several obstacles remain. The development of neutralizing human antibodies can be minimized by constructing chimeric humanized MoAbs or recombinant single chain antibodies. New technologies to design highaffinity human MoAbs include the phage display technique 35 or transgenic 'humanized' mice. 36 Recombinant DNA technology can be used for site-directed modifications in order to select high-affinity antibodies.
The selection of antigen-negative tumor cell variants among the heterogeneous tumor cell population can, at least in part, be circumvented by the application of MoAb cocktails, ie mixtures of MoAbs against different antigens on the same target cell, or by active tumor-specific vaccination approaches. Such cocktails of MoAbs have successfully been used to purge bone marrow from residual lymphoma cells, 37 with a combination of three antibodies depleting the malignant cells in a magnitude of up to 6 logs.
The ultimate goal to use monoclonal antibodies to cure patients with relapsed or refractory lymphomas has not yet been reached. However, we have learned to use monoclonal antibodies and their conjugates. Preliminary results are promising and large clinical trials in patients with residual disease are required to analyze the role of monoclonal antibodies in more detail.
